Should GnRH agonist therapy be continued beyond 5 years (along with an aromatase inhibitor) in young pre-menopausal women with high risk breast cancer who continue to have ovarian function at 5 years of endocrine treatment?

My response of 'No' assumes that the patient has been on OFS (with either tamoxifen or an AI) for her first 5 years of adjuvant endocrine therapy. We have no data on benefit of OFS beyond 5 years, the benefit on continuing AI beyond 5 years is very modest, especially in regards distant recurrence, w...